168619-04-3

Basic information

• Product Name: 3'-FLUORO-BIPHENYL-3-CARBOXYLIC ACID
• Synonyms: RARECHEM AL BE 1343;3-BIPHENYL-3'-FLUORO-CARBOXYLIC ACID;3'-FLUORO[1,1'-BIPHENYL]-3-CARBOXYLIC ACID;3'-FLUORO-BIPHENYL-3-CARBOXYLIC ACID;AKOS B025019;AKOS BAR-0025;3-(3-FLUOROPHENYL)BENZOIC ACID;CHEMBRDG-BB 4400451
• CAS NO: 168619-04-3
• Molecular Formula: C13H9FO2
• Molecular Weight: 216.21
• Product Categories: pharmacetical
• Mol File: 168619-04-3.mol

Chemical Properties

• Boiling Point: 392.9 °C at 760 mmHg
• Flash Point: 191.4 °C
• Appearance: /
• Density: 1.261 g/cm³
• PKA: 4.05±0.10(Predicted)
• CAS DataBase Reference: 3'-FLUORO-BIPHENYL-3-CARBOXYLIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 3'-FLUORO-BIPHENYL-3-CARBOXYLIC ACID(168619-04-3)
• EPA Substance Registry System: 3'-FLUORO-BIPHENYL-3-CARBOXYLIC ACID(168619-04-3)

Safety Data

• Hazard Codes: Xi,Xn
• Statements: 36/37/38-22
• Safety Statements: 26-36/37/39
• Hazardous Substances Data: 168619-04-3(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
3'-Fluoro-biphenyl-3-carboxylic acid is used as a building block in organic synthesis for the preparation of various pharmaceuticals and agrochemicals. Its unique structure and fluorine substitution contribute to the development of new compounds with enhanced properties and applications.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, 3'-Fluoro-biphenyl-3-carboxylic acid is utilized as a key intermediate for the synthesis of biologically active compounds. Its presence in the molecular structure can influence the pharmacokinetics, pharmacodynamics, and overall efficacy of the resulting pharmaceuticals.
Used in Pharmaceutical Intermediates:
3'-Fluoro-biphenyl-3-carboxylic acid is employed as a pharmaceutical intermediate, playing a crucial role in the development of new drugs. Its unique properties and reactivity enable the creation of diverse drug candidates with potential therapeutic applications.
Used in Structure-Activity Relationship Studies:
3'-FLUORO-BIPHENYL-3-CARBOXYLIC ACID is also used in the study of structure-activity relationships in organic molecules. By analyzing the effects of the fluorine substitution and carboxylic acid group on the biological activity of the resulting compounds, researchers can gain insights into the design and optimization of more effective and selective drugs.

Upstream product

• 585-76-2 m-bromobenzoic acid 
• 768-35-4 3-fluorophenylboronic acid 

Downstream Products

• 1427406-77-6 N-(2,6-difluoro-3-hydroxy-phenyl)-3-(3-fluorophenyl)benzamide 
• 1427406-78-7 2,4-difluoro-3-[[3-(3-fluorophenyl)phenyl]methylamino]phenol 
• 1427406-79-8 C₂₃H₂₀F₃NO₃ 
• 1427330-92-4 2-[2,4-difluoro-3-[[3-(3-fluorophenyl)phenyl]methylamino]phenoxy]acetic acid 

Relevant articles and documents

A focused fragment library targeting the antibiotic resistance enzyme - Oxacillinase-48: Synthesis, structural evaluation and inhibitor design

β-Lactam antibiotics are of utmost importance when treating bacterial infections in the medical community. However, currently their utility is threatened by the emergence and spread of β-lactam resistance. The most prevalent resistance mechanism to β-lactam antibiotics is expression of β-lactamase enzymes. One way to overcome resistance caused by β-lactamases, is the development of β-lactamase inhibitors and today several β-lactamase inhibitors e.g. avibactam, are approved in the clinic. Our focus is the oxacillinase-48 (OXA-48), an enzyme reported to spread rapidly across the world and commonly identified in Escherichia coli and Klebsiella pneumoniae. To guide inhibitor design, we used diversely substituted 3-aryl and 3-heteroaryl benzoic acids to probe the active site of OXA-48 for useful enzyme-inhibitor interactions. In the presented study, a focused fragment library containing 49 3-substituted benzoic acid derivatives were synthesised and biochemically characterized. Based on crystallographic data from 33 fragment-enzyme complexes, the fragments could be classified into R1 or R2 binders by their overall binding conformation in relation to the binding of the R1 and R2 side groups of imipenem. Moreover, binding interactions attractive for future inhibitor design were found and their usefulness explored by the rational design and evaluation of merged inhibitors from orthogonally binding fragments. The best inhibitors among the resulting 3,5-disubstituted benzoic acids showed inhibitory potential in the low micromolar range (IC50 = 2.9 μM). For these inhibitors, the complex X-ray structures revealed non-covalent binding to Arg250, Arg214 and Tyr211 in the active site and the interactions observed with the mono-substituted fragments were also identified in the merged structures.

ANILINE DERIVATIVES,THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION

The present invention relates to aniline derivatives, to their preparation and to their therapeutic application.